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Abstract
Salivary duct carcinomas (SDCs) and adenoid cystic carcinomas (ACCs) are the most aggressive and the most
frequent carcinomas of the salivary glands, respectively. Little is known about them in terms of molecular/
biochemical characterization and conventional treatments are ineffective. On cryopreserved material, we analyzed
the expression/activation status of TRK-A, HER-2/neu, and KIT receptors by means of immunoprecipitation and
Western blot analysis experiments, and the presence of their cognate ligands by means of Western blot analysis
and/or reverse transcription–polymerase chain reaction in 9 SDCs, 12 ACCs, and 8 normal glands. The amplifica-
tion status of HER-2/neu was also investigated by means of fluorescent in situ hybridization analysis on fixed ma-
terial. The receptor tyrosine kinase (RTK)–deregulated profile of the SDCs was characterized by the overexpression
of activated TRK-A in the presence of its ligand, and the overexpression of HER-2/neu sustained by gene amplifi-
cation. The RTK signature of the ACCs was represented by the overexpression of activated KIT and TRK-A and their
cognate ligands, and the overexpression of activated HER-2/neu, in the absence of gene amplification, possibly
sustained by epidermal growth factor receptor heterodimerization. In conclusion, SDCs and ACCs, although shar-
ing TRK-A autocrine loop activation, have different pathologically activated RTK-deregulated profiles that may be
potential targets for pharmacological RTK inhibitors.
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Introduction
Receptor tyrosine kinases (RTKs) are often deregulated in human
cancers, and, therefore, they represent an attractive target for selec-
tive pharmacological inhibitors. As novel pharmacological RTK in-
hibitors are being increasingly developed, exploiting the expression/
activation patterns of RTKs in tumors poorly responsive to conven-
tional treatments could lead to significant therapeutic advances. This
group of tumors includes carcinomas of salivary gland origin, an un-
common and heterogeneous group of tumors, whose molecular and
biochemical characteristics have been little investigated.
Salivary duct carcinoma is a rare salivary gland adenocarcinoma
mainly affecting the parotid gland, that has striking histologic simi-
larities to breast carcinomas and distinct aggressive clinical behavior
with early nodal and visceral metastases [1]. Adenoid cystic carci-
noma is the most common histotype mainly involving the parotid,
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the submandibular, and minor salivary glands. It has a typical pro-
tracted course with local recurrences and late hematogenous me-
tastases. In both tumors, conventional pharmacological treatments
are ineffective.
Immunophenotype analyses have found neurotrophic tyrosine ki-
nase receptor, type 1 (TRK-A) expression in normal salivary gland tis-
sue [2], and KITand HER-2/neu overexpression in specimens of ACCs
and SDCs, along with myoepithelial carcinomas, lymphoepithelioma-
like carcinomas, and mucoepidermoid carcinomas [3–6]. Furthermore,
HER-2/neu gene amplification has been observed in HER-2/neu–
overexpressing SDCs [7,8] and mucoepidermoid carcinomas [6].
TRK-A and nerve growth factor (NGF) have been found in nor-
mal human salivary gland by means of immunohistochemistry and
Western blot analysis, respectively [2,9], and in ACC specimens by
means of immunohistochemistry [10]. It has been reported that
deregulated expression of TRK-A (and TRK-B, TRK-C, and their
cognate ligands) correlates with malignant transformation and tumor
progression in both prostate cancer cell lines and tissues [11,12] and
that all the three TRKs are overexpressed in pancreatic ductal adeno-
carcinomas [13,14]. TRK-A is a 140-kDa RTK for NGF. It repre-
sents a pharmacological target for CEP-701 (Cephalon, Inc., West
Chester, PA), an orally active compound already used in hormone-
refractory prostate cancer patients [12,15–17].
HER-2/neu protein is 63% to 100% overexpressed in SDCs [18–
21], and amplification of the gene has been reported in more than
50% of the SDCs overexpressing HER-2/neu [7,8]. Gene ampli-
fication is the most common pathological activation mechanism re-
ported for HER-2/neu, mainly described in breast carcinoma [22].
The HER-2/neu product is a 185-kDa glycoprotein belonging to
the family of epidermal growth factor receptor (EGFR), inhibited
by herceptin (Genentech Inc., South San Francisco, CA), a mono-
clonal antibody directed against the extracellular domain [23], effective
in breast cancer [24].
KIT expression has been reported in normal salivary gland tissue
[25], among malignant epithelial carcinomas in ACC, lymphoepithe-
lial, and myoepithelial carcinomas [3], and exceedingly rare in SDC
[26]. c-kit encodes a 145-kDa RTK glycoprotein structurally related
to platelet-derived growth factor receptor, whose ligand is the stem cell
factor (SCF). The pathologic activation of KIT in gastrointestinal
stromal tumors, sustained by activating mutations [27], is inhibited
by imatinib (Novartis, Basel, Switzerland) by binding to the ATP
pocket site. Little is known about KIT receptor activation in ACCs,
although the lack of gain of function mutations [3,28] makes the
autocrine loop the most likely activating involved mechanism.
We analyzed the expression/activation status of TRK-A, HER-2/neu,
and KITreceptors in a series of SDCs and ACCs by means of immuno-
precipitation (IP) and Western blot analysis experiments, and the
presence of their cognate ligands by means of reverse transcription–
polymerase chain reaction (RT-PCR). Eight normal glands were ana-
lyzed in the same way as reference controls. The amplification status
of the HER-2/neu gene was also investigated by means of fluorescent
in situ hybridization (FISH) analysis.
Materials and Methods
Patients
We studied cryopreserved material from 21 salivary gland carci-
nomas (9 SDCs and 12 ACCs; 19 primary tumors and 2 recurrences),
collected at Istituto Nazionale Tumori of Milan between 1991 and
2004. The diagnoses were made on paraffin-embedded material.
Among ACCs, six belonged to cribriform variety and one to tubular
one, whereas five cases were composite tumors with two components
(cribriform/tubular or cribriform/solid), four cases, or three compo-
nents (cribriform/tubular/solid), one case. All the cases were reviewed
by at least two pathologists and re-reviewed by one of the authors (S.P.)
with a good reproducibility (100%). Seven of the SDCs originated
from the parotid gland, two from the submandibular gland; the ACCs
developed in the parotid gland (n = 4), submandibular gland (n = 3),
sublingual gland (n = 1), and in minor salivary glands (n = 4). Their
clinic-pathological features are summarized in Table 1.
Normal control salivary gland specimens were obtained from eight
patients who underwent surgical procedures for benign parotid con-
ditions or submandibular gland removal for neck surgery in head and
neck malignancies. Written informed consent was obtained in
all cases.
Before molecular analysis, every specimen was checked for quality
by hematoxylin and eosin staining of a representative section.
Biochemical Analysis
Positive controls. An NIH3T3 cell line overexpressing proto-
TRK-A (E25) [29] and the SKBR3 human breast cancer cell line
(American Type Culture Collection, Manassas, VA) were respectively
used in the IP and Western blot analysis experiments as TRK-A and
HER-2/neu–positive controls; a Δ559 cell line overexpressing a mu-
tated KIT receptor was used as the KIT-positive control [30]; and
NGF 2.5 S (01-125; Upstate, Lake Placid, NY) was used as the posi-
tive control, when evaluating the NGF expression in Western blot
analysis experiments.
Immunoprecipitation and Western blot analysis. The proteins
were extracted and IP experiments were performed as described else-
where [31].
TRK-A protein was immunoprecipitated from 1 mg of protein
lysate using 300 ng of monoclonal MGR12 antibody, kindly sup-
plied by Dr. Tagliabue [32]; the positive control was 200 μg of
E25 cell line lysate.
HER-2/neu protein was immunoprecipitated from 1 mg of pro-
tein lysate derived from the unbound proteins of anti–TRK-A IP
using 2 μg of c-neu Ab-3 monoclonal antibody (Oncogene Re-
search Products, San Diego, CA); the positive control was 300 μg
of SKBR3 lysate.
KIT was immunoprecipitated from the unbound proteins derived
from the successive IPs of TRK-A and HER-2/neu using 360 ng
of Ab-3 (K45) monoclonal antibody directed against the receptor
(Neomarkers, Fremont, CA); the positive control was 500 μg of Δ559
cell line lysate.
The samples were loaded on a 6.5% (TRK-A) or 8% (KIT and
HER-2/neu) acrylamide gel and blotted to a polyvinylidene fluoride
membrane (Millipore Corporation, Bedford, MA). To reveal the
status of receptor phosphorylation, the membrane was incubated
with antiphosphotyrosine mouse monoclonal antibody (Clone
4G10; Upstate). To measure receptor expression, the filters were
stripped and incubated with the following antibodies: Trk (C-14)
sc-11 (Santa Cruz Biotechnology, Santa Cruz, CA) for TRK-A;
c-kit (c-19) sc-168 (Santa Cruz Biotechnology) for KIT; and c-neu
Ab-3 for HER-2/neu.
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To normalize the IP and Western blot experiments, after α–TRK-A
IP, 50 μg of unbound proteins from each tissue sample was loaded
onto a 10% acrylamide gel and blotted; the blots were then incubated
with α-actin antibody (actin H-196: sc-7210; Santa Cruz Biotech-
nology). To verify NGF expression in the normal and carcinoma sam-
ples, 50 μg of protein lysate was loaded onto a 15% acrylamide gel and
blotted; the blots were then incubated with α-NGF antibody (NGF
H-20: sc-548; Santa Cruz Biotechnology). Nerve growth factor 2.5 S
10 μg was also loaded as a positive control.
Fluorescent In Situ Hybridization
Fluorescent in situ hybridization on cytologic specimens and
paraffin-embedded tissue sections. Touch imprints were obtained
from the frozen specimens of 2 of 8 normal salivary glands, 8 of
9 SDCs, and the 12 ACCs by means of apposition on precleaned
slides. In one SDC case (case No. 7; Table 1) for which no cryo-
preserved material was available, the analysis was performed on sec-
tions obtained from tissue block. Slides and sections were treated as
previously described [33,34], and the same was true for the assess-
ment of Her-2 amplification [34].
Reverse Transcription–Polymerase Chain Reaction
Total RNA was extracted and reverse-transcribed as described else-
where [35], and the efficiency of the reaction was assessed by amplify-
ing the β-actin housekeeping gene. For the NGF and SCF analyses,
the PCR amplifications were performed as previously described [9,35].
Results
TRK-A
Biochemical analysis. Both normal and tumor cases were analyzed
for TRK-A receptor expression and phosphorylation by means of IP
experiments on total protein extracts. The experiments were normal-
ized by Western blot analysis using the same aliquots of α–TRK-A
unbound proteins and incubating the membrane with α-actin anti-
body (Figure 1). The results are summarized in Table 1.
Normal tissues. TRK-A was expressed in all normal salivary
gland specimens and visualized as a 140-kDa band corresponding to
the fully glycosylated receptor form. Hybridization of the same mem-
brane with α-PTyr antibody revealed that TRK-A was phosphorylated
(and therefore active) in all cases. We arbitrarily indicated these cases as
2+/P. In Figure 1A, six of eight cases are represented.
Salivary duct carcinomas. TRK-A was underexpressed in two
cases (marked as 1+/P), expressed as in the normal controls but
highly phosphorylated in one (marked as 2+/PP), and overexpressed
and phosphorylated in six (marked as 3+/P and 3+/PP), which are
also shown in Figure 1B. The 140-kDa band of the wild type mature
receptor was observed in all of the expressing cases.
Adenoid cystic carcinomas. Eight ACC tissue samples showed
the same pattern of TRK-A expression and activation (2+/P) as the
one observed in the normal controls. One showed less expressed
Table 1. Summary of the Clinic-Pathologic Features and Results.
Case Sex/Age (years) Tumor Localization TRK-A (IP) NGF (RT-PCR) NGF (WB) HER-2 (IP) HER-2 (FISH) KIT (IP) SCF (RT-PCR)
Control 1 F/43 Parotid 2+/P n.d. n.d. − n.d. 2+ n.d.
Control 2 M/42 Parotid 2+/P + n.d. − n.d. 2+ +
Control 3 F/30 Parotid 2+/P n.d. n.d. − n.d. 2+ n.d.
Control 4 F/62 Parotid 2+/P n.d. n.d. − n.d. 2+ n.d.
Control 5 F/83 Parotid 2+/P + n.d. − n.d. 2+ +
Control 6 M/84 Parotid 2+/P + n.d. − n.d. 2+ +
Control 7 M/62 Parotid 2+/P + + 1+/P − 2+ +
Control 8 F/54 Submandibular 2+/P n.d. + 1+/P − 2+ n.d.
SDC 1 F/71 Submandibular 3+/P + + − − 2+ +
SDC 2 F/65 Parotid 3+/P + + 3+/PP + (HSR) 1+ +
SDC 3 M/63 Parotid 1+/P + + 3+/PP + (HSR) − +
SDC 4 M/79 Parotid 3+/PP + + 3+/P + (HSR) − +
SDC 5 M/58 Parotid 3+/PP + + − + (DM) − +
SDC 6 M/69 Parotid 2+/PP + + − − − +
SDC 7 F/70 Submandibular 1+/P + + − − 1+ +
SDC 8 F/48 Parotid 3+/P + + − + (DM) 3+/P +
SDC 9 M/62 Parotid 3+/PP + + 1+/P +(HSR) 1+ +
ACC 1 c M/55 Submandibular 2+/P + + 2+/P − 2+ +
ACC 2 c M/17 Parotid 2+/P + + 2+/P − 2+ +
ACC 3 c, t F/41 Submandibular 1+/PP n.v. + − − 2+ n.v.
ACC 4 c F/46 Parotid 2+/P + + − − 3+ +
ACC 5 c, t, s F/51 Minor 2+/P + + − − 3+ +
ACC 6 t F/52 Minor 2+/P + + 2+/P − 3+/P +
ACC 7 c, s F/34 Sublingual 2+/P + + 2+/P − 2+ +
ACC 8 c F/54 Submandibular 3+/PP + + 1+/P − 3+ +
ACC 9 c, t F/55 Minor 2+/P + + 1+/P − 3+/P +
ACC 10 c, s F/62 Parotid 2+/P + + − − 3+/P +
ACC 11 c F/55 Minor* 3+/PP + + 1+/P − 3+/P +
ACC 12 c M/39 Parotid* 3+/P + + 1+/PP − 3+/P +
The expression and phosphorylation level detected in normal salivary glands was considered as baseline for each receptor (2+/P for TRK-A; 1+/P for HER-2/neu; 2+ for KIT).
c indicates cribriform variety; DM, double minute; F, female; HSR, homogeneously staining region; M , male; n.d., not done; n.v., not evaluable; P, phosphorylation of the receptor; PP, high level of
receptor phosphorylation; s, solid variety; t, tubular variety.
*Recurrence.
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but highly phosphorylated TRK-A (1+/PP), and three showed over-
expressed and phosphorylated TRK-A (3+/P and 3+/PP). In Fig-
ure 1C , six representative cases are showed.
In brief, TRK-A expression/activation was observed in all of
the normal samples (considered baseline or threshold expression);
TRK-A overexpression (cases specified as 3+/P and 3+/PP) was ob-
served in 6 of 9 SDCs and 3 of 12 ACCs.
Reverse Transcription–Polymerase Chain Reaction
Nerve growth factor expression. The presence of NGF tran-
script was analyzed in four normal samples and all of tumor specimens
by RT-PCR. All the samples were positive for the 74-bp ligand band
(Figure 1D). Unfortunately, one ACC (No. 3 of the Table 1) was not
evaluable because of material unsuitability. Western blot analysis con-
firmed the NGF expression as a 14-kDa band in all analyzed samples
(two normal and all tumor specimens; Figure 1E and Table 1).
HER-2/neu
Biochemical analysis. Due to the scarcity of normal and tumor
material HER-2/neu expression and activation were analyzed by
means of IP and Western blot experiments using unbound proteins
derived from α–TRK-A IP. Results are summarized in Table 1.
Normal tissues. Hybridization with α–HER-2/neu antibody re-
vealed a band of 185 kDa in two of eight normal salivary gland tissue
samples, where hybridization with α-PTyr antibody showed that
HER-2/neu was phosphorylated and therefore active. These two
cases are reported in Figure 2A and are identified as 1+/P.
Salivary duct carcinomas. Three of nine SDCs overexpressed
phosphorylated HER-2/neu (indicated as 3+/P and 3+/PP), one
had the same expression/activation status as the two normal controls
(indicated as 1+/P) and five cases resulted negative. In Figure 2B, the
three overexpressing cases and three negative cases are reported.
Adenoid cystic carcinomas. Four of 12 ACCs showed the same
HER-2/neu expression and receptor activation as the two normal
controls and were indicated as 1+/P (although No. 12 had a higher
phosphorylation level), another four showed a higher level of phos-
phorylated HER-2/neu expression (indicated as 2+/P) and other
four resulted negative. In Figure 2C , the four overexpressing cases
and two negative cases are showed.
Fluorescent In Situ Hybridization
Normal tissues. A normal double signal was present in the two
cases analyzed (Nos. 7 and 8 of Table 1).
Figure 1. TRK-A expression and activation. For each sample, total protein extracts were immunoprecipitated with α–TRK-A antibody, run
on gel, and blotted with α-PTyr antibody (PTyr panel) for receptor phosphorylation status and with α–TRK-A antibody (TRK-A panel) for
receptor expression. Normalization of the experiment was done using 50 μg of unbound proteins and blot analysis with α-actin anti-
body (actin panel). Lane C+: positive control (E25 cell line). Lane numbers correspond to the cases reported in Table 1. (A) Expression of
TRK-A and its phosphorylation in six normal salivary glands. (B) Expression of TRK-A and its phosphorylation in six overexpressing SDC
cases. (C) Expression of TRK-A and its phosphorylation in six ACC cases. (D) Expression detected by RT-PCR experiments of NGF tran-
script in normal and tumoral salivary glands. A total of 1 μl of cDNA was used as template for each NGF and β-actin gene amplification
reaction; 10 μl of PCR were loaded on 2% agarose gel. (E) Expression of NGF in normal and tumoral salivary glands. A total of 50 μg of
protein lysate was loaded onto a 15% acrylamide gel and blotted with α-NGF antibody. Lane C: positive control (NGF 2.5 S).
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Salivary duct carcinomas. HER-2/neu amplification was de-
tected in six cases: four as homogeneously staining regions (HSR, al-
though the signal was very low in No. 9) and two as double minutes
(DM; Figure 2D).
Correlations between the SDC biochemical and FISH analyses.
Three of the HSR-positive cases were associated with overexpressed
and phosphorylated HER-2/neu receptors (3+/P and 3+/PP); the
level of expression in No. 9 was as low as in the normal controls
(1+/P). On the contrary, the two DM cases lacked HER-2/neu pro-
tein expression and phosphorylation.
Adenoid cystic carcinomas. HER-2/neu gene amplification was
never detected.
In brief, HER-2/neu expression was found in only two of the nor-
mal salivary glands. HER-2/neu overexpression and phosphorylation
were observed in 3 of the 9 SDCs (in which HSR amplification also
occurred) and in 4 of the 12 ACCs.
KIT
Biochemical analysis. The protein extracts obtained from the
8 normal and 21 salivary carcinomas were analyzed for KITexpression
and activation by means of IP and Western blot experiments using un-
bound proteins derived from the previous α–TRK-A and α–HER-2/
neu IPs. Whereas this procedure allowed us to detect in the positive
samples the related protein, in most of the cases, we failed to detect
any phosphorylation of the receptor, most likely, because after two IP
rounds dephosphorylation by phosphatase has occurred. The results
are summarized in Table 1.
Normal tissues. Hybridization with α-KIT antibody revealed a
band of 145 kDa corresponding to the mature form of the receptor (in-
dicated as 2+); hybridization of the same blot with α-PTyr antibody
showed the absence of receptor phosphorylation in all cases (data not
shown). In Figure 3A, KITexpression of six of eight cases is represented.
Salivary duct carcinomas. Four of the nine SDCs did not ex-
press KIT. It was expressed to the same extent as in the normal controls
Figure 2. HER-2/neu expression and activation. For each sample, protein lysate derived from the unbound proteins of anti–TRK-A IP was
immunoprecipitated with α–HER-2/neu antibody, run on gel, and blotted with α-PTyr antibody (PTyr panel) for receptor phosphorylation
status and with α–HER-2/neu antibody (HER-2/neu panel) for receptor expression. Lane C+: positive control (SKBR3 cell line). Lane
numbers correspond to the cases reported in Table 1. (A) Expression of HER-2/neu and its phosphorylation in the two normal salivary
glands that express the receptor. (B) Expression of HER-2/neu and its phosphorylation in six SDC cases. (C) Expression of HER-2/neu
and its phosphorylation in six ACC cases. (D) HER-2/neu gene amplification analysis in SDC cases. Fluorescent in situ hybridization
on imprint specimens. Chromosome 17 probe is labeled in Spectrum Green; HER-2/neu locus–specific probe is labeled in Spectrum
Orange. Nuclei are counterstained with DAPI. Upper panel: amplification in HSR in SDC case No. 2 of Table 1. Lower panel: amplifica-
tion in DM in SDC case No. 5 of Table 1. Single-copy gene signals are indicated by arrows.
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in one case (indicated as 2+), underexpressed in three (indicated as 1+),
and overexpressed in one (indicated as 3+/P). Hybridization with
α-PTyr antibody showed the absence of bands in all but one case
(No. 8). In Figure 3B, some representative cases are reported.
Adenoid cystic carcinomas. All 12 specimens expressed KIT.
Eight overexpressed the 145-kDa receptor form and were indicated
as 3+ and 3+/P; in the remaining four, KIT expression was the same
as in the normal controls (indicated as 2+), although No. 3 overex-
pressed the 125-kDa form. Receptor phosphorylation was observed
in five cases (indicated as 3+/P). In Figure 3C , expression of KIT
receptor of both expressing and overexpressing cases are showed.
In brief, KIT receptor was expressed in the normal salivary glands
and, in comparison with these, was overexpressed in 1 of the 9 SDCs
and 8 of the 12 ACCs.
Reverse transcription–polymerase chain reaction
Stem cell factor expression. Reverse transcription–polymerase
chain reaction was used to identify SCF transcript in four normal
and in all SDC and ACC samples. All of the samples (except for
ACC No. 3) were positive, showing two bands with the expected mo-
lecular weights of 494 bp (SCF-L) and 409 bp (SCF-S; Figure 3D and
Table 1). L-stem cell factor was more expressed than S-stem cell factor.
Results in ACC No. 3 were unavailable for material unsuitability.
Discussion
The present molecular/biochemical analyses show that SDCs and
ACCs, despite sharing TRK-A autocrine/paracrine loop activation,
have different RTK-deregulation profiles. Salivary duct carcinoma
profile is characterized by overexpression/activation of TRK-A in
the presence of its ligand coupled with overexpression/activation of
HER-2/neu sustained by gene amplification. Adenoid cystic carci-
noma profile is characterized instead by overexpression/activation
of KIT and TRK-A coupled with the presence of their cognate li-
gands, and no amplification-related overexpression of HER-2/neu.
The involvement of TRK-A in SDCs is not unexpected because
this tumor has a number of morphologic and immunophenotype
similarities with ductal prostate, pancreas and breast carcinomas,
in which development and progression have been associated with
TRK-A receptor, both in preclinical and clinical studies. Furthermore,
TRK-A/NGF coexpression promotes malignant transformation and
tumor progression in the prostate [11,12] and characterizes breast can-
cer cell lines [9]. Interestingly, TRK-A expression in breast cancer cell
lines has been associated with HER-2/neu activation by NGF, thus
suggesting that HER-2/neu is activated by means of heterodimeriza-
tion [36]. Moreover, TRK-A mRNA and/or protein expression has
been detected in surgical specimens of infiltrating ductal breast carci-
nomas investigated by means of RT-PCR/Western blot analysis [36]
and in ductal adenocarcinomas of the pancreas analyzed by means
of immunohistochemistry [13,14].
The present study provides the first demonstration that the mo-
lecular profile of SDCs is characterized by the overexpression of
Figure 3. KIT expression and activation. For each sample, protein lysate derived from the unbound proteins of anti–TRK-A and anti–HER-
2/neu IPs was immunoprecipitated with α-KIT antibody, run on gel, and blotted with α-KIT antibody (KIT panel) for receptor expression.
Lane C+: positive control (Δ559 cell line). Lane numbers correspond to the cases reported in Table 1. (A) Expression of KIT in six normal
salivary glands. KIT expression detected in these samples was in keeping with the immunohistochemistry decoration we observed (right
panel), using Dako CD117 antibody. (B) Expression of KIT in six SDC cases. Absence of KIT expression by immunohistochemistry ex-
periments was also detected in tumoral specimens; normal salivary duct and mastocytes, positive in-built controls, are indicated by
arrows. (C) Expression of KIT in six ACC cases. The high KIT expression is confirmed by the strong CD117 positivity detected in these
tumoral samples. (D) Expression of SCF transcript detected by RT-PCR experiment in normal and tumoral salivary glands. A total of 1 μl
of cDNA was used as template for each SCF and β-actin gene amplification reaction; 10 μl of PCR were loaded on 2% agarose gel. In the
case of SCF amplification, two bands of the expected molecular weight were detected (L = 494 bp and S = 409 bp).
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phosphorylated TRK-A and the coexpression of its cognate ligand,
supporting the presence of an autocrine/paracrine loop activation
of this gene, for which no activation mutations have yet been re-
ported in carcinomas [37,38] and overexpression, due to its promoter
methylation, is described in pancreatic cancer [39].
Regarding HER-2/neu, our data confirm that the results of IP/
Western blot analysis experiments closely correlate with those of
FISH analysis being all HER-2/neu 3+–expressing cases also HER-
2/neu–amplified. These results, which recapitulated what observed in
ductal breast carcinoma [40], suggest that herceptin should be con-
sidered for the treatment of SDC as already reported [41–43]. How-
ever, because TRK-A activation or coactivation is the most frequent
RTK deregulation in SDCs, combined treatments based on TRK-A
inhibitors and herceptin should be considered. Remarkably, in two
cases of SDC, the amplification is DM-sustained and is correlated
with the absence of protein expression. If confirmed, the latter find-
ing has important implications because it is expected that herceptin
will be ineffective in cases carrying DM amplifications.
Regarding ACC, our results point out that the overexpression of
activated KIT and TRK-A in presence of their ligands seems to char-
acterize this tumor profile. The lack of KIT phosphorylation in our
normal and tumoral samples is probably attributable to our meth-
odological approach, because KIT was immunoprecipitated after
two rounds of IPs from unbound α–TRK-A and α–HER-2/neu
proteins. This procedure could have affected KIT phosphorylation
status. This assumption is supported by the fact that transcript analysis
revealed the presence in all the samples of the two biologically ac-
tive SCF isoforms corresponding to the soluble- (L) and membrane-
associated (S) ligands in both normal and tumoral KIT–expressing
tissues. Therefore, an autocrine loop also seems to be the most likely
mechanism of KIT activation in ACCs, a finding that is strengthened
by c-kit gene analyses showing the absence of activating mutations
in overexpressing ACCs [3,28] (data not shown). We have previously
demonstrated a similar KIT activation mechanism in small cell lung
cancers, which expressed activated receptor in presence of SCF and
wild type c-DNA [35]. Because it has been found that compounds,
such as sunitinib (Sugen Inc., South San Francisco, CA), are effective
on cell lines, in which KIT is activated by means of an autocrine loop
[44,45], whereas imatinib (evaluated in phase II clinical trials of un-
resectable or metastatic KIT-expressing ACCs) has proved to be inef-
fective [46,47] and considering the frequent activation of TRK-A,
the application of wild type KIT inhibitors in addition to TRK-A in-
hibitors may represent a suitable pharmacological option in ACC.
Furthermore, the overexpression of HER-2/neu in the absence of
gene amplification and coupled with the EGFR immunophenotypic
positivity (data not shown) we observed in the same ACCs strongly
suggests that HER-2/neu may also be activated by means of hetero-
dimerization with EGFR in some cases. This finding, if confirmed
by coimmunoprecipitation experiments, might further extend treat-
ment choices to EGFR inhibitors, in particular to antibodies that block
ligand binding.
In conclusion, we demonstrated that TRK-A deregulation is a
characteristic shared by SDC and ACC that, however, carry different
deregulated RTK profiles representing potential targets for RTK in-
hibitors administered alone or in combination. Future developments
should include the development of drugs capable of inhibiting the
secondary transducers activated by TRK-A, KIT, HER-2/neu, and
EGFR shared by existing downstream pathways. However, the rele-
vance of RTK inhibitors remains confined to advanced cases (recur-
rence and/or metastasis), being surgery the primary modality of
treatment of primary salivary gland carcinomas.
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